Production of thiamine mononitrate and hydrochloride at industrial scale relies on a convergent assembly of the pyrimidine and thiazole moieties, with 5-(2-chloroethyl)-4-methylthiazole hydrochloride serving as the electrophilic synthon for the latter. The hydrochloride salt is neutralized in situ using 30% w/w aqueous NaOH at 5–10°C to liberate the free base, which is then extracted into dichloromethane; phase separation must occur within 15 minutes to limit dimerization of the chloroethyl side chain. The dried organic phase is concentrated under reduced pressure at ≤25°C to a residual water content of <0.05% (Karl Fischer titration, ISO 760:1978). Coupling with 2-methyl-4-amino-5-aminomethylpyrimidine dihydrochloride proceeds in ethanol/water (3:1 v/v) at 55–60°C for 4–6 hours under a nitrogen blanket, with the pyrimidine to thiazole molar ratio maintained at 1:1.05–1:1.10 to drive consumption of the more costly pyrimidine component. Post-reaction pH is adjusted to 4.0–4.5 with concentrated HCl, triggering crystallization of thiamine hydrochloride; crystal size distribution is controlled through a linear cooling ramp of 0.3°C/min from 60°C to 5°C in a jacketed stirred vessel. Crystal fines <50 µm are removed via a hydrocyclone bypass to maintain filtration throughput above 200 kg/m²/h on a centrifuge basket. Granulation for direct compression formulations is carried out in a fluidised-bed dryer fitted with a Wurster insert, where inlet air temperature is held at 70°C and the spray rate of aqueous binder (Povidone K30, 3 wt% relative to thiamine) is 15 g/min/kg batch. Regulatory compliance for the final thiamine hydrochloride and mononitrate products adheres to Ph. Eur. monograph 0303 (Thiamine Hydrochloride) and USP–NF monograph Thiamine Hydrochloride, including identity tests A–C, heavy metals limit ≤10 ppm, and related substances by HPLC with a reporting threshold of 0.05%. Residual dichloromethane is monitored per ICH Q3C Option 1, gas chromatography–headspace (Ph. Eur. 2.4.24), with a permissible daily exposure of 6.0 mg/person.
When the thiazole intermediate is diverted to the production of thiamine mononitrate, the crude hydrochloride salt is first converted to the free base in aqueous ethanol at pH 8.0–8.5 using sodium carbonate, then precipitated as the nitrate by addition of stoichiometric nitric acid (1.0 equiv relative to thiamine) at 40°C. The precipitate is collected and recrystallized from 70% aqueous ethanol containing 0.1% activated carbon to scavenge color bodies. Particle size specification for the mononitrate grade intended for dry food fortification mixes requires a D50 of 150–250 µm and a span (D90–D10)/D50 of ≤1.4, determined by laser diffraction (ISO 13320:2020). Terminal sterilization of the crystalline powder is not applied; instead, bioburden control during crystallization and drying is governed by a microbiological limit of total aerobic mesophiles ≤100 CFU/g and absence of Escherichia coli in 1 g (Ph. Eur. 5.1.4). The primary application scope covers oral solid-dose vitamin B1 supplements, enriched wheat flour premixes meeting Codex STAN 234-1999, and parenteral grade thiamine hydrochloride for injection vials, where the endotoxin limit is ≤0.5 EU/mg (Ph. Eur. 2.6.14).
How Does the Free-Base Activation Step Influence Epimer Purity in Roxatidine Acetate Synthesis?
In the preparation of roxatidine acetate — an H₂-receptor antagonist indicated for peptic ulcer and gastritis — 5-(2-chloroethyl)-4-methylthiazole hydrochloride is the alkylating component introduced late in the linear sequence. Prior to reaction, the salt undergoes a critical activation sequence: it is dissolved in anhydrous dimethylformamide (DMF, water content ≤100 ppm by KF) and treated with finely milled potassium carbonate (1.2 molar equivalents, particle size D90 ≤75 µm) at 25°C under argon for 30 minutes, forming a suspension of the free base together with precipitated KCl. This suspension is directly added via a metering pump to a DMF solution of N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]amine at 80°C over 2 hours, achieving a final amine-to-thiazole stoichiometry of 1:1.01. The heterogeneous nature of the potassium carbonate slurry has been shown to generate a localized basic microenvironment (pH ~10 at the solid–liquid interface) sufficient to promote elimination of the chloroethyl side chain to the corresponding vinyl derivative — a degredant isolated at 0.3–0.8 area% by GC-MS if the carbonate is not pre-dried at 150°C in vacuo for 6 hours. The alkylation mixture is maintained at 80°C for an additional 3 hours post-addition, then quenched into ice-water and extracted with ethyl acetate. The crude roxatidine free base is purified over a short-path silica gel column (Merck grade 60, 15–40 µm) using dichloromethane:methanol:ammonia (90:9:1), and the epimer ratio (R/S at the piperidine-adjacent carbon) is measured by chiral HPLC (Chiralpak AD-H, 250 × 4.6 mm, hexane:isopropanol:diethylamine 85:15:0.1); an epimer ratio exceeding 98.5:1.5 is required to avoid additional diastereomeric purification steps downstream. Acetylation to roxatidine acetate is accomplished with acetic anhydride (1.15 equiv) in pyridine at 0–5°C followed by precipitation in ice-water and recrystallization from ethanol. Throughout the synthesis, compliance with ICH Q7 for active pharmaceutical ingredient intermediates is evidenced by documented batch records that capture critical process parameters: jacket temperature control accuracy ±1°C, addition rate limits, and agitator tip speed 0.8–1.2 m/s. Residual solvent testing of the final intermediate prior to acetylation must demonstrate DMF ≤880 ppm and pyridine ≤200 ppm to align with ICH Q3C Option 2 limits, employing a validated gas chromatography method calibrated against certified reference materials traceable to NIST SRM 2264a. The only class-1 solvent monitored is 1,2-dichloroethane, with a rejection limit of ≤5 ppm as it is avoided entirely in the process; this is confirmed by a dedicated GC-ECD analysis at each batch release.
During commercial-scale execution in a 2000 L glass-lined reactor equipped with a retreat curve impeller, exotherm management during the potassium carbonate addition is achieved by recirculating chilled glycol at -5°C through the jacket, clamping the internal temperature to ≤30°C. Filtration of the KCl by-product is performed across a 0.5 µm sintered metal candle filter prior to amine charging; inadequate filtration leads to abrasive wear of the downstream gear pump and iron contamination in the crude above 5 ppm. The terminal pharmaceutical product, roxatidine acetate, is administered as an immediate-release tablet at doses of 75 mg and must conform to dissolution test criteria (USP apparatus 2, 50 rpm, 900 mL 0.1 N HCl, Q = 80% at 45 min). Importantly, the thiazole hydrochloride intermediate cannot be stored for extended periods after opening due to hygroscopicity; a validated in-use period of 14 days under dry nitrogen blanket at 25°C/≤10% RH has been established through accelerated stability testing incorporating FTIR monitoring of the hydrochloride C=O overtone region.
Feed-Grade Thiamine Mononitrate Production: Granulation Uniformity and Residual Acetone Limits
A parallel manufacturing chain supplies thiamine mononitrate meeting nutritional fortification specifications for monogastric and ruminant feed. Here, the identical 5-(2-chloroethyl)-4-methylthiazole hydrochloride starting material is subjected to a condensed reaction sequence that eliminates the activated carbon treatment and accepts a broader color specification (absorbance at 430 nm ≤0.15 for a 5% w/v aqueous solution, compared to ≤0.05 for pharmaceutical grade). The coupling step with 2-methyl-4-amino-5-aminomethylpyrimidine is performed in methanol/water (1.5:1) at reflux (66°C) for 3 hours, using a pyrimidine-to-thiazole ratio of 1:1.03, with the temperature deliberately elevated to suppress the formation of 4-methyl-5-vinylthiazole by degrading any unconverted chloroethyl intermediate before work-up. This process variant reduces methanol volume by 18% relative to the pharmacopeial route and shortens the cycle time by 1.5 hours, however it produces an increase in the level of 2-[2-(4-methylthiazol-5-yl)ethoxy]ethanol detected at ≤0.2% by HPLC. The mononitrate isolation uses acetone as a precipitation antisolvent (water/acetone 1:3 v/v), generating crystals with a D50 of 80–120 µm; the lower particle size necessitates a second granulation step in a high-shear mixer-granulator (Gral 10 type, chopper speed 1500 rpm, impeller 200 rpm) with hydroxypropyl methylcellulose (2.5 wt%) as binder to achieve a feed premix carrier spreadability index of >90 on a Heubach dustmeter (procedure per DIN 33893-2). Residual acetone is controlled to ≤50 ppm per Commission Regulation (EU) 1831/2003 Annex III, analyzed by headspace GC against an external standard traceable to ERM certified reference materials. Heavy metal limits in the feed-grade product are set at arsenic ≤2 ppm, lead ≤10 ppm, and mercury ≤0.1 ppm (ICP-MS, AOAC 2015.01); cadmium is not specified in regional pharmacopoeial compendia but is internally monitored at ≤1 ppm to satisfy FAMI-QS certification. The terminal product, a flowable microgranulate packed in 25 kg three-ply paper bags with an LDPE inner liner, is integrated into poultry basal diets at a typical inclusion rate of 2–4 mg/kg feed to prevent thiamine deficiency-induced polyneuritis, and into swine starter rations at 1.5 mg/kg complete feed, in alignment with National Research Council (NRC) recommendations.
In the synthesis of benfotiamine — an S-benzoyl derivative of thiamine with enhanced lipid solubility and improved transketolase activation in sciatic nerve tissue — the hydrochloride salt of the thiazole intermediate is first neutralized to the free base in anhydrous tetrahydrofuran using sodium hydride (1.0 equivalent, 60% dispersion in mineral oil) at 0–5°C, requiring a solvent water content below 50 ppm to prevent runaway hydrogen generation. The free base is not isolated but instead added dropwise to a solution comprising O-benzoylthiamine disulfide dissolved in THF/DMF (4:1) under a nitrogen atmosphere, in the presence of triphenylphosphine (1.2 equiv) and diisopropyl azodicarboxylate (1.2 equiv) at -10°C; the reaction proceeds via a Mitsunobu-type desulfurization coupling, with the thiazole moiety acting as a leaving group facilitator. After aqueous work-up and flash chromatography, benfotiamine is crystallized from isopropanol at 5°C, yielding a polymorph (Form A) characterized by a melting endotherm onset at 132.5°C (DSC, 10°C/min, nitrogen purge 50 mL/min) and an XRPD pattern matching reference code BENZOT01. Quality attributes for the dietary supplement ingredient are governed by USP–NF Benfotiamine monograph (where officially listed) and additionally by the European Pharmacopoeia standard for related substances control: total impurities ≤1.0%, single unknown impurity ≤0.1%, and residual sodium hydride reaction by-products (NaCl, mineral oil) demonstrating a sulfated ash ≤0.1%. The production process is executed in a kilogram-scale kilo-lab under ISO 7 (Class 10,000) cleanroom conditions where charging of sodium hydride is performed inside a glove box purged to <1% oxygen to eliminate ignition hazards. Disposable static-dissipative isolators are preferred over fixed stainless steel isolators due to the risk of sodium ion leaching into the THF hydration layer. The final benfotiamine powder is filled into HDPE drums with double polyethylene liners, headspace replaced by nitrogen to ≥97% residual oxygen, and labeled with a retest period of 24 months when stored at 15–25°C.
When an Alkylating Thiazole Building Block Requires Scavenger Resins for Residual Chloride Removal
Small-scale medicinal chemistry campaigns and contract research programs employ 5-(2-chloroethyl)-4-methylthiazole hydrochloride as a versatile C-5 functionalized thiazole synthon for generating compound libraries targeting bromodomain proteins and kinase hinge regions. Typical experimental protocols involve liberation of the free base using polymer-bound morpholine resin (3.2 mmol/g loading, 1.5 equiv) in anhydrous acetonitrile, performed in a microwave vial at 40°C for 10 minutes with orbital shaking at 800 rpm. The supernatant, containing the alkyl chloride, is transferred by positive-displacement pipette into a plate containing pre-weighed amine or thiol nucleophiles (substitution scope includes primary aliphatic amines, aryl piperazines, and thiophenols) and heated to 80°C in a Biotage Initiator microwave synthesizer with simultaneous cooling, maintaining a constant absorbance power of 100 W for 20 minutes. To ensure compliance with the purity specifications requested by the partnering biotech entity (typically ≥95% by ELSD-UPLC at 214 nm), the crude reaction mixtures are filtered through a silica-supported tosyl chloride scavenger cartridge (500 mg, preconditioned with acetonitrile) to sequester unreacted nucleophile, then evaporated in a Genevac EZ-2 centrifugal evaporator at 30°C and 8 mbar. Characterization includes 1H NMR (400 MHz, CDCl3) confirming the intact 4-methyl resonance at δ 2.42 ppm and the disappearance of the chloroethyl triplet at δ 3.78 ppm, together with HRMS (ESI-TOF) accurate mass within 3 ppm mass error. The synthesized derivatives are registered in the client’s central corporate collection as DMSO stocks at 10 mM concentration, tested for aqueous solubility by nephelometry in PBS pH 7.4, and released only if the solubility exceeds 50 µM. The CRO supplying the intermediate batch provides a certificate of analysis indicating purity ≥98.0% (HPLC at 254 nm), residual ethanol ≤300 ppm, and a chloride content assay of 17.8–18.2% by potentiometric titration (Metrohm Ag-Titrode) against a standard solution of silver nitrate 0.1 N certified against NIST SRM 136f. Since the final library compounds are not destined for human administration, formal ICH guidelines do not apply; however an ISO 9001:2015 quality management system governs work instruction adherence, and a Materials Safety Data Sheet compliant with Regulation (EC) 1907/2006 (REACH) Annex II accompanies every shipment. Operational risk: the hydrochloride salt, if mishandled in hot dimethyl sulfoxide solution, can undergo hydrolysis to the primary alcohol (4-methyl-5-(2-hydroxyethyl)thiazole) at a first-order rate constant k = 1.2 × 10-4 s-1 at 80°C, mandating dry solvent conditions and pre-heating of the resin suspension to avoid premature hydroxyl impurity levels exceeding 0.5% at the moment of coupling.
